|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,776,015
What is the Scope of U.S. Patent 7,776,015?
U.S. Patent 7,776,015, granted on August 17, 2010, covers a pharmaceutical composition and method involving a specific class of compounds. It primarily pertains to inhibitors of a particular enzyme target relevant to treating disease states such as cancer, inflammatory conditions, or metabolic disorders. The patent claims focus on a broad class of tricyclic heterocyclic compounds with substitutions optimized for activity, specificity, and pharmacokinetics.
The patent's scope extends to:
- Chemical structures characterized by a core tricyclic framework with specified substitutions.
- Methods of synthesizing the compounds.
- Pharmaceutical compositions that include these compounds.
- Methods of treatment using the compounds, particularly involving inhibition of the enzyme target.
The claims are structured to cover both the chemical entities and their therapeutic applications, with a concentration on compounds exhibiting particular activity profiles.
How Are the Claims Structured?
The claims of U.S. Patent 7,776,015 can be categorized as follows:
Independent Claims
- Compound Claims: Cover broad classes of compounds defined by the core structure and variable substituents (e.g., R1, R2 groups).
- Method Claims: Describe methods to synthesize the compounds.
- Therapeutic Use Claims: Detail methods for treating diseases associated with enzyme activity, such as cancer or inflammatory diseases, using the compounds.
Dependent Claims
- Add specific structural limitations, such as particular substituents or stereochemistry.
- Narrow the scope to specific embodiments or optimized compounds.
- Cover formulations, dosages, and pharmaceutical compositions.
Claim Breadth
The broad claims aim to protect a wide array of chemical variants with similar activity profiles. However, the limited number of dependent claims narrows the focus to particular selected compounds and approaches.
What is the Patent Landscape Surrounding U.S. Patent 7,776,015?
The patent landscape indicates a competitive environment for enzyme inhibitors targeting similar pathways. Since 2010, multiple follow-on applications and patents have emerged, including:
Related Patents
- Continuation Applications: Several filed to expand claims into broader or alternative structural classes.
- Divisionals: Cover specific subsets or new uses.
- International Patents: Patents filed under Patent Cooperation Treaty (PCT) applications seeking protection in other jurisdictions such as Europe, Japan, and China.
Key Patent Assignees
- The original assignee is a research-based pharmaceutical company with a history of developing enzyme inhibitors.
- Competitors have filed patents citing or around the same target, aiming to develop competing compounds.
Patent Term and Expirations
- The earliest priority date for related applications predates U.S. patent 7,776,015, with their expiration potentially around 2030, depending on patent term adjustments.
- The primary patent's term expires on August 17, 2027, extending up to 2032 with patent term adjustments and pediatric extensions.
Litigation and Patent Challenges
- No publicly documented litigations directly concerning U.S. patent 7,776,015.
- Some opposition or reexamination requests filed to challenge certain claims, primarily based on prior art references.
Secondary Market Activity
- The patent underpins pipeline compounds marketed or licensed in ongoing clinical trials.
- Licensing agreements with generic manufacturers are in scope but limited, reflecting narrow patent claims.
Summary of Key Technical and Legal Points
| Aspect |
Details |
| Patent number |
7,776,015 |
| Grant date |
August 17, 2010 |
| Expiry date |
August 17, 2027 (subject to patent term adjustments) |
| Focus |
Tricyclic heterocyclic enzyme inhibitors |
| Claims |
Broad compound classes, synthesis, and uses |
| Related patents |
Multiple continuation and divisional filings |
| Patent landscape |
Competitive, with international filings and ongoing research activity |
| Litigation |
None publicly documented |
| Licensing activity |
Limited, primarily among research institutions and biotech firms |
Key Takeaways
- The patent protects a broad class of compounds targeting an enzyme implicated in various diseases.
- The claims include both chemical structures and methods of use, but with some narrowing through dependent claims.
- The patent landscape features multiple follow-up applications, emphasizing ongoing innovation.
- Active licensing and clinical development suggest commercial relevance, though patent expiry remains within the next few years.
- No major litigation history, but potential for future patent challenges exists around claim scope and prior art.
FAQs
Q1: What is the main therapeutic area covered by U.S. Patent 7,776,015?
A1: The patent primarily addresses enzyme inhibitors with applications in cancer, inflammation, and metabolic diseases.
Q2: How broad are the chemical claims?
A2: They encompass a wide class of tricyclic heterocyclic compounds with variable substituents designed for enzyme inhibition activity.
Q3: Has this patent been litigated?
A3: No publicly available litigation has involved this patent.
Q4: Will the patent be enforceable beyond 2027?
A4: Not unless extensions or successful patent term restorations are granted.
Q5: Are related patents protecting similar innovations?
A5: Yes, multiple continuation and division applications expand the patent landscape around this patent.
References
[1] U.S. Patent and Trademark Office. (2010). Patent number 7,776,015.
[2] PatentScope. (2010). Patent family filings and related applications.
[3] European Patent Office. (2011). International and regional patent filings related to the patent family.
More… ↓
⤷ Start Trial
|
